# IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma

> **NCT03381183** · PHASE1 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 19 (actual)

## Conditions studied

- Squamous Cell Carcinoma
- Squamous Cell Carcinoma of the Head and Neck
- Metastatic Squamous Cell Carcinoma
- Oral Cavity Squamous Cell Carcinoma
- Oropharynx Squamous Cell Carcinoma
- Paranasal Sinus Squamous Cell Carcinoma
- Hypopharynx Squamous Cell Carcinoma
- Larynx Squamous Cell Carcinoma

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** IRX-2 Regimen

## Key facts

- **NCT ID:** NCT03381183
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-21
- **Primary completion:** 2022-05-12
- **Final completion:** 2023-06-30
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2025-12-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03381183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03381183, "IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03381183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*